Show simple item record

A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison

dc.contributor.authorJones, R. J.
dc.contributor.authorHussain, S. A.
dc.contributor.authorBirtle, A. J.
dc.contributor.authorSong, Yee Pei
dc.contributor.authorEnting, D.
dc.contributor.authorFaust, G.
dc.contributor.authorHilman, S.
dc.contributor.authorJagdev, S.
dc.contributor.authorMcGovern, U. B.
dc.contributor.authorParikh, O.
dc.contributor.authorLewis, A.
dc.contributor.authorSoulis, E.
dc.contributor.authorTrevethan, A.
dc.contributor.authorCrabb, S. J.
dc.contributor.authorPowles, T.
dc.date.accessioned2023-02-23T15:17:24Z
dc.date.available2023-02-23T15:17:24Z
dc.date.issued2022en
dc.identifier.citationJones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, et al. A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison. Journal of Clinical Oncology. 2022 Jun;40(17). PubMed PMID: WOS:000891791500024.en
dc.identifier.doi10.1200/JCO.2022.40.17_suppl.LBA4505en
dc.identifier.urihttp://hdl.handle.net/10541/626048
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.17_suppl.LBA4505en
dc.titleA randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparisonen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Glasgow, Glasgowen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record